Evaluation of Iron Profile in Sudanese Patients with Cardiovascular Disorders under Multiple Transfusions
Background: iron overload is the most common complication in patients who revived multiple red blood transfusions to correct the anemia.
Objective this study aimed to evaluate the iron profile (serum iron, ferritin, total iron binding capacity (TIBC) and transferrin saturation percentage) in Sudanese patients with cardiovascular disorders, who revived multiple red blood transfusions.
Material and methods this was a case control study conducted during August 2015, in Alneelain University, Faculty of Medical Laboratory Science. A total of 100 participants were enrolled in this study, 60 were Sudanese patients diagnosed with cardiovascular disorders and who received multiple blood transfusions at Alshaab Teaching Hospital Khartoum, Sudan; their mean age was (50.6+12.7) years, designated as a patient’s group. Other 40 subjects were normal healthy who received no blood transfusions as control group; their mean age was 45.5+11.4 years. Venous blood was collected from all participants, and then the serum was prepared from clotted blood. The iron profile (serum ferritin, serum iron and total iron binding capacity) was carried out using automated chemical analyzer (MINDRAY BS 200-China).Data were analyzed employing statistical package for social sciences (SPSS) version 20. The p value less than 0.05 was considered significant.
Result this study showed that the serum iron and serum ferritin were statistically significantly higher while the TIBC and transferrin saturation percentage were statistically significantly lower in cardiovascular patients who received regular blood cell, compared with those normal ho received regular packed cell with p value (0.01,0.04,0.04 and 0.04) respectively.
Conclusion iron overload was present in Sudanese cardiovascular patients who received no multiple blood transfusion compared to those normal who received no blood cell.
2- Angelucci E.Another Step Forward in Iron Chelation Therapy.ActaHaematol.2015;134(4):231-2.
3- Leitch HA. Hematologic improvement with Iron chelation therapy in acquired anemias. Eur J Haematol. 2016; 96(6):551-2.
4- Kontoghiorghe CN, KontoghiorghesGJ.New developments and controversies in iron metabolism and iron chelation therapy.World J Methodol. 2016; 6(1):1- 19.
3- AltesA,Sanz C, Bruguera M. Hereditary hemochromatosis. Problems in diagnosis and treatment. Medicina Clinica.2015;144(9):424-8.
6- Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994; 331(9):567-73
4- Bajoria R, Chatterjee R. Hypogonadotrophichypogonadism and diminished gonadal reserve accounts for dysfunctional gametogenesis in thalassaemia patients with iron overload presenting
5- Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis. 2011; 47(1):33-40.
6- Vincent JL, Baron J-F, Reinhart K, et al. ABC (Anemia and Blood Transfusion in Critical Care) Investigators.Anemia and blood transfusion in critically ill patients. JAMA2002;288:1499-507
7- Carson J, Duff A, Poses R, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet1996;348:1055-60
8- Wu W.C, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med2001;345:1230-6
9- Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality
in patients with advanced heart failure. J Am Coll Cardiol2002;39:1780-6
10- Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation2005;111:2042-9.